Voyager Therapeutics (VYGR) to Post Earnings on Wednesday

Posted by Stanley Muller on Aug 3rd, 2026

Voyager Therapeutics (NASDAQ:VYGR – Get Free Report) is anticipated to release its Q2 2026 results after the market closes on Wednesday, August 5th. Analysts expect the company to announce earnings of ($0.4838) per share and revenue of $4.5190 million for the quarter. Parties can find conference call details on the company’s upcoming Q2 2026 earning report page for the latest details on the call scheduled for Friday, August 14, 2026 at 4:00 PM ET.

Voyager Therapeutics (NASDAQ:VYGR – Get Free Report) last issued its quarterly earnings results on Thursday, May 7th. The company reported ($0.47) EPS for the quarter, beating the consensus estimate of ($0.54) by $0.07. The company had revenue of $1.19 million during the quarter, compared to analysts’ expectations of $8.79 million. Voyager Therapeutics had a negative net margin of 319.61% and a negative return on equity of 55.97%. On average, analysts expect Voyager Therapeutics to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Voyager Therapeutics Price Performance

NASDAQ:VYGR opened at $3.03 on Monday. Voyager Therapeutics has a 52 week low of $2.88 and a 52 week high of $5.55. The company has a fifty day simple moving average of $3.48 and a two-hundred day simple moving average of $3.76. The company has a market cap of $183.07 million, a price-to-earnings ratio of -1.54 and a beta of 1.31.

Hedge Funds Weigh In On Voyager Therapeutics

A number of institutional investors and hedge funds have recently modified their holdings of VYGR. Wexford Capital LP purchased a new position in Voyager Therapeutics in the third quarter valued at $42,000. CIBC Asset Management Inc purchased a new stake in Voyager Therapeutics during the 4th quarter worth about $45,000. Coldstream Capital Management Inc. acquired a new position in shares of Voyager Therapeutics during the 3rd quarter worth about $55,000. Occudo Quantitative Strategies LP acquired a new position in shares of Voyager Therapeutics during the 2nd quarter worth about $78,000. Finally, Jane Street Group LLC increased its holdings in shares of Voyager Therapeutics by 92.6% in the 2nd quarter. Jane Street Group LLC now owns 27,844 shares of the company’s stock valued at $87,000 after acquiring an additional 13,389 shares during the last quarter. Institutional investors and hedge funds own 48.03% of the company’s stock.

Analyst Ratings Changes

Several analysts have recently issued reports on the company. Wall Street Zen lowered Voyager Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, May 9th. Weiss Ratings restated a “sell (d-)” rating on shares of Voyager Therapeutics in a report on Monday, July 13th. Finally, HC Wainwright reaffirmed a “buy” rating on shares of Voyager Therapeutics in a research report on Monday, July 20th. One investment analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $16.50.

View Our Latest Stock Report on VYGR

About Voyager Therapeutics

(Get Free Report)

Voyager Therapeutics, Inc is a clinical-stage biotechnology company focused on the development of gene therapies for serious neurological diseases. The company’s core activities center on the design and delivery of engineered adeno-associated viral (AAV) vectors tailored to target cells in the brain and central nervous system. Through its proprietary CapsidMap and VectorMap platforms, Voyager aims to enhance vector potency, specificity and durability to address diseases with high unmet medical need.

The firm’s pipeline includes several AAV-based candidates in preclinical and early clinical development.